---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-24-000360"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:41:58.461234+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation

## Summary
- Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.
- At pre-specified week 2 endpoint, effect size=0.79, suggesting early onset of action.
- Interim results compare favorably to Brexpiprazole's Phase 3 (Cohen's d 0.35, LS mean -5.32).
- Trial ongoing (n=26 interim); final results may differ as enrollment continues in US and Canada.
- IGC-AD1 targets CB1 receptor, neuroinflammation, and inflammasome-3 pathways.

## SEC filing metadata
- accession: 0001185185-24-000360
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518524000360/0001185185-24-000360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518524000360/igcpharma20240320_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-24-000360
- JSON: https://secwatch.observer/filing/0001185185-24-000360.json
- Plain text: https://secwatch.observer/filing/0001185185-24-000360.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.